No Data
Shenzhen Kangtai Biological Products (300601.SZ): The 20-valent pneumococcal polysaccharide conjugate vaccine has started phase II clinical trials.
GlobeNews March 31st丨Shenzhen Kangtai Biological Products (300601.SZ) announced that its wholly-owned subsidiary, Peking Minhai Biotechnology Co., Ltd. (referred to as "Minhai Biotechnology"), has completed the preparation for the Phase II clinical trial of the 20-valent pneumococcal polysaccharide conjugate vaccine, initiating the Phase II clinical trial, and successfully enrolling the first subject recently. The 20-valent pneumococcal polysaccharide conjugate vaccine is suitable for infants and children aged 2 months to 5 years. After administering this vaccine, the body can generate an immune response to prevent infectious diseases caused by 20 types of pneumococcal serotypes. Currently, the 20-valent pneumococcal polysaccharide conjugate vaccine has been launched overseas.
Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?
① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.
Shenzhen Kangtai Biological Products (300601.SZ): Signed the "Economic Development Cooperation Agreement" and the "List of Terms".
On March 21, Glonghui reported that Shenzhen Kangtai Biological Products (300601.SZ) announced that it would convene the third meeting of the eighth Board of Directors on March 21, 2025, to review and approve the proposal on signing and establishing a joint venture through external investment. After careful discussion, the company plans to establish a deep strategic partnership with AstraZeneca Investment (China) Co., Ltd. (hereinafter referred to as "AstraZeneca") focusing on vaccines, and to set up a joint venture in the Peking Economic and Technological Development Zone (hereinafter referred to as "Development Zone"), serving as a platform for developing innovative vaccines in China, targeting the Chinese market and
Is Shenzhen Kangtai Biological Products (SZSE:300601) A Risky Investment?
Shenzhen Kangtai Biological Products (300601.SZ): Received the summary report of the Phase I and III clinical trials for the adsorbed tetanus vaccine.
Gelonghui, March 3rd丨Shenzhen Kangtai Biological Products (300601.SZ) announced that its wholly-owned subsidiary Peking Minhai Biological Technology Co., Ltd. (referred to as "Minhai Biology") recently received the summary report of the clinical trial phases I/III for the adsorbed tetanus vaccine. The clinical research phase work for the adsorbed tetanus vaccine developed by Minhai Biology has been successfully completed. The research results show that the adsorbed tetanus vaccine developed by Minhai Biology has good safety and immunogenicity for adult immunization. The acquisition of this summary report for the adsorbed tetanus vaccine clinical trial phases I/III indicates that the adsorbed tetanus vaccine meets the essential conditions for production application, which is important for the company's development.
Shenzhen Kangtai Biological Products (SZSE:300601) Shareholders Have Endured a 76% Loss From Investing in the Stock Five Years Ago
The Three-year Shareholder Returns and Company Earnings Persist Lower as Shenzhen Kangtai Biological Products (SZSE:300601) Stock Falls a Further 4.4% in Past Week
